In summary, we developed a pH-responsive drug delivery vehicle for receptor-selective drug delivery to cancer cells with high FRα expression and identified guidelines for selection of candidate PI3K/mTOR inhibitors for treatment of cancers sensitive to aberrant PI3K signaling inhibition. This evidence concerns the gene FOLR1 and cancer.